DWA
KALV

Dorsey Wright & Associates’s KalVista Pharmaceuticals KALV Stock Holding History

Dorsey Wright & Associates’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-700
Closed -$13K – 325
2020
Q4 		$13K Buy
+700
New +$12K ﹤0.01% 266
2019
Q2 		– Sell
-433
Closed -$12K – 311
2019
Q1 		$12K Sell
433
-429
-50% -$9.3K ﹤0.01% 159
2018
Q4 		$17K Buy
+862
New +$17.3K 0.01% 157

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Dorsey Wright & Associates's KALV Position: Q1 2021 in Review

Dorsey Wright & Associates sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 700 shares — an estimated $13K sold.

Dorsey Wright & Associates first reported a position in KALV in Q4 2018 and held it in 3 quarters. The position peaked at $17K in Q4 2018. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

  • Dorsey Wright & Associates reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 700 KalVista Pharmaceuticals shares in Q1 2021, an estimated $13K.
  • Dorsey Wright & Associates first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's KalVista Pharmaceuticals position peaked at $17K in Q4 2018.
  • 117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on Dorsey Wright & Associates's 13F filing for Q1 2021, filed 27 Apr 2021.